<![CDATA[Otsuka Pharmaceutical Co., Ltd. 보도자료 - 뉴스와이어]]>https://www.newswire.co.kr/?md=A10&act=article&no=21001>Thu, 14 May 2026 02:44:29 +0900Copyright (c) 2004~2026 Korea Newswire All rights reservedko-KR<![CDATA[Efficacy Results of Otsuka’s Delamanid (Deltyba™) for Extensively Drug-Resistant Tuberculosis (XDR-TB) Published in the New England Journal of Medicine]]>https://www.newswire.co.kr/newsRead.php?no=798000Fri, 17 Jul 2015 10:20:00 +0900<![CDATA[뉴잉글랜드 의학 저널에 게재된 광범위 내성 결핵(XDR-TB)에 대한 오츠카제약(Otsuka)의 델라마니드(Deltyba®) 효능 결과]]>https://www.newswire.co.kr/newsRead.php?no=798003Fri, 17 Jul 2015 10:20:00 +0900<![CDATA[Otsuka Pharmaceutical to Acquire Avanir Pharmaceuticals]]>https://www.newswire.co.kr/newsRead.php?no=776317Fri, 05 Dec 2014 16:40:00 +0900<![CDATA[오츠카제약, 아바니어 파마슈티컬스 인수키로]]>https://www.newswire.co.kr/newsRead.php?no=776320Fri, 05 Dec 2014 16:40:00 +0900<![CDATA[Otsuka Wins European Marketing Authorization for Deltyba™ (delamanid)]]>https://www.newswire.co.kr/newsRead.php?no=749224Wed, 07 May 2014 18:05:00 +0900<![CDATA[오츠카제약의 신약 델티바(Deltyba®, 델라마니드), 유럽 시장 판매 승인 획득]]>https://www.newswire.co.kr/newsRead.php?no=749225Wed, 07 May 2014 18:05:00 +0900<![CDATA[Otsuka Pharmaceutical‘s Samsca® Approved in Japan as the World’s First Drug Therapy for ADPKD, a Rare Kidney Disease]]>https://www.newswire.co.kr/newsRead.php?no=743413Tue, 25 Mar 2014 17:00:00 +0900<![CDATA[오츠카제약 ‘삼스카’(Samsca®), 일본에서 희귀 신장 질환 ADPKD의 세계 첫 치료제로 승인]]>https://www.newswire.co.kr/newsRead.php?no=743414Tue, 25 Mar 2014 17:00:00 +0900<![CDATA[CHMP Recommends Otsuka's Deltyba™ (delamanid) for EU Approval for Treatment of Multidrug-Resistant Tuberculosis (MDR-TB) in Combination with Optimized Background Regimen (OBR)]]>https://www.newswire.co.kr/newsRead.php?no=724986Tue, 26 Nov 2013 09:00:00 +0900